Skip to main content
main-content
Erschienen in: Lasers in Medical Science 9/2020

06.06.2020 | Original Article

The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study

verfasst von: Rungsima Wanitphakdeedecha, Francesca Sy-Alvarado, Poramin Patthamalai, Thanya Techapichetvanich, Sasima Eimpunth, Woraphong Manuskiatti

Erschienen in: Lasers in Medical Science | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

This split-face, double-blind, randomized controlled study examines the efficacy of fractional thulium laser (FTL)–assisted delivery of topical tranexamic acid (TXA) compared with FTL alone as a treatment option for melasma. Forty-six adults with Fitzpatrick skin types III–V and recalcitrant melasma underwent four weekly treatments with fractional 1927-nm thulium laser on both sides of the face. Immediately after treatment, TXA was applied to one side of the face and normal saline solution (NSS) to the contralateral side as control under occlusion. Melanin index (MI), modified MASI (mMASI), and patients’ self-assessed improvement scores were measured at baseline, 1 week, 4 weeks, and 3- and 6 months after the final treatment and were examined statistically with a paired sample t test with significance set at p ≤ 0.05. The majority of the participants (95.7%, n = 44) were female with Fitzpatrick skin type IV (82.6%) and a mean age of 48.0 ± 10.0 years. Twenty-nine individuals were able to be followed up until the 6-month assessment. Significant improvement from baseline was seen in both the MI and mMASI scores for both the TXA and control sides at 3 months, with no statistically significant difference between sides. By the 6th month, significant differences in MI and mMASI scores from baseline were still noted, except in the MI for controls. The patients’ self-assessment showed similar patterns. No serious adverse events were reported for either group. A regimen of FTL-assisted delivery of TXA over a 4-week period is a safe and effective treatment option for melasma, producing significant improvement up to 3 months. Results further would suggest a repeat regimen every 3 months could be useful for treatment of recalcitrant melasma.
Literatur
1.
Zurück zum Zitat Kwon SH, Park KC (2014) Melasma and common pigmentary dermatoses in Asian individuals and an overview of their treatment. J Clin Investig Dermatol 2(1):8 Kwon SH, Park KC (2014) Melasma and common pigmentary dermatoses in Asian individuals and an overview of their treatment. J Clin Investig Dermatol 2(1):8
2.
Zurück zum Zitat Newcomer VD, Lindberg MC, Sternberg TH (1961) A melanosis of the face (“chloasma”). Arch Dermatol 83(2):284–299 CrossRef Newcomer VD, Lindberg MC, Sternberg TH (1961) A melanosis of the face (“chloasma”). Arch Dermatol 83(2):284–299 CrossRef
3.
Zurück zum Zitat Grimes PE (1995) Melasma: etiologic and therapeutic considerations. Arch Dermatol 131(12):1453–1457 CrossRef Grimes PE (1995) Melasma: etiologic and therapeutic considerations. Arch Dermatol 131(12):1453–1457 CrossRef
4.
Zurück zum Zitat Kim EH, Kim YC, Lee ES, Kang HY (2007) The vascular characteristics of melasma. J Dermatol Sci 46(2):111–116 CrossRef Kim EH, Kim YC, Lee ES, Kang HY (2007) The vascular characteristics of melasma. J Dermatol Sci 46(2):111–116 CrossRef
5.
Zurück zum Zitat Pathak MA, Riley FC, Fitzpatrick TB (1962) Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light. J Invest Dermatol 39:435–443 CrossRef Pathak MA, Riley FC, Fitzpatrick TB (1962) Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light. J Invest Dermatol 39:435–443 CrossRef
6.
Zurück zum Zitat Suggs AK, Hamill SS, Friedman PM (2018) Melasma: update on management. Semin Cutan Med Surg 37(4):217–225 CrossRef Suggs AK, Hamill SS, Friedman PM (2018) Melasma: update on management. Semin Cutan Med Surg 37(4):217–225 CrossRef
7.
Zurück zum Zitat Rivas S, Pandya AG (2013) Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol 14(5):359–376 CrossRef Rivas S, Pandya AG (2013) Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol 14(5):359–376 CrossRef
8.
Zurück zum Zitat Sarkar R, Aurangabadkar S, Salim T, Das A et al (2017) Lasers in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group. Indian J Dermatol 62(6):585–590 Sarkar R, Aurangabadkar S, Salim T, Das A et al (2017) Lasers in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group. Indian J Dermatol 62(6):585–590
9.
Zurück zum Zitat Kang H, Kim J, Goo B (2011) The dual toning technique for melasma treatment with the 1064 nm Nd: YAG laser: a preliminary study. Laser Ther 20(3):189–194 CrossRef Kang H, Kim J, Goo B (2011) The dual toning technique for melasma treatment with the 1064 nm Nd: YAG laser: a preliminary study. Laser Ther 20(3):189–194 CrossRef
10.
Zurück zum Zitat Kim JH, Kim H, Park HC, Kim IH (2010) Subcellular selective photothermolysis of melanosomes in adult zebrafish skin following 1064-nm Q-switched Nd:YAG laser irradiation. J Invest Dermatol 130(9):2333–2335 CrossRef Kim JH, Kim H, Park HC, Kim IH (2010) Subcellular selective photothermolysis of melanosomes in adult zebrafish skin following 1064-nm Q-switched Nd:YAG laser irradiation. J Invest Dermatol 130(9):2333–2335 CrossRef
11.
Zurück zum Zitat Mun JY, Jeong SY, Kim JH, Han SS, Kim IH (2011) A low fluence Q-switched Nd:YAG laser modifies the 3D structure of melanocyte and ultrastructure of melanosome by subcellular-selective photothermolysis. J Electron Microsc 60(1):11–18 CrossRef Mun JY, Jeong SY, Kim JH, Han SS, Kim IH (2011) A low fluence Q-switched Nd:YAG laser modifies the 3D structure of melanocyte and ultrastructure of melanosome by subcellular-selective photothermolysis. J Electron Microsc 60(1):11–18 CrossRef
12.
Zurück zum Zitat Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH (2010) A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med 42(8):712–719 CrossRef Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH (2010) A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med 42(8):712–719 CrossRef
13.
Zurück zum Zitat Wattanakrai P, Mornchan R, Eimpunth S (2010) Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg 36(1):76–87 CrossRef Wattanakrai P, Mornchan R, Eimpunth S (2010) Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg 36(1):76–87 CrossRef
14.
Zurück zum Zitat Perper M, Eber AE, Fayne R, Verne SH, Magno RJ et al (2017) Tranexamic acid in the treatment of melasma: a review of the literature. Am J Clin Dermatol 18(3):373–381 CrossRef Perper M, Eber AE, Fayne R, Verne SH, Magno RJ et al (2017) Tranexamic acid in the treatment of melasma: a review of the literature. Am J Clin Dermatol 18(3):373–381 CrossRef
16.
Zurück zum Zitat Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS (2017) Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol 97(7):776–781 CrossRef Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS (2017) Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol 97(7):776–781 CrossRef
17.
Zurück zum Zitat Sheu SL (2018) Treatment of melasma using tranexamic acid: what’s known and what’s next. Cutis 101(2):E7–E8 Sheu SL (2018) Treatment of melasma using tranexamic acid: what’s known and what’s next. Cutis 101(2):E7–E8
19.
Zurück zum Zitat Zhu CY, Li Y, Sun QN, Takada A, Kawada A (2019) Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol 29(1):55–58 Zhu CY, Li Y, Sun QN, Takada A, Kawada A (2019) Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol 29(1):55–58
20.
Zurück zum Zitat Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY (2016) Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 41(5):480–485 CrossRef Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY (2016) Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 41(5):480–485 CrossRef
21.
Zurück zum Zitat Bagherani N, Smoller BR (2015) The efficacy of topical tranexamic acid in the treatment of melasma. Dermatol Ther 28(4):265 CrossRef Bagherani N, Smoller BR (2015) The efficacy of topical tranexamic acid in the treatment of melasma. Dermatol Ther 28(4):265 CrossRef
22.
Zurück zum Zitat Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A (2017) Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther (Heidelb) 7(3):417–424 CrossRef Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A (2017) Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther (Heidelb) 7(3):417–424 CrossRef
24.
Zurück zum Zitat Xu Y, Ma R, Juliandri J, Wang X, Xu B et al (2017) Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: a randomized, self-controlled, split-face study. Medicine 96(19):e6897 CrossRef Xu Y, Ma R, Juliandri J, Wang X, Xu B et al (2017) Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: a randomized, self-controlled, split-face study. Medicine 96(19):e6897 CrossRef
25.
Zurück zum Zitat Laothaworn V, Juntongjin P (2018) Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. J Cosmet Laser Ther 20(6):320–325 CrossRef Laothaworn V, Juntongjin P (2018) Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. J Cosmet Laser Ther 20(6):320–325 CrossRef
26.
Zurück zum Zitat Cho SB, Goo BL, Zheng Z, Yoo KH et al (2018) Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study. Lasers Med Sci 33(4):851–859 CrossRef Cho SB, Goo BL, Zheng Z, Yoo KH et al (2018) Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study. Lasers Med Sci 33(4):851–859 CrossRef
27.
Zurück zum Zitat Lee HM, Haw S, Kim JK, Chang SE, Lee MW (2013) Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin. Dermatol Surg 39(6):879–888 CrossRef Lee HM, Haw S, Kim JK, Chang SE, Lee MW (2013) Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin. Dermatol Surg 39(6):879–888 CrossRef
Metadaten
Titel
The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study
verfasst von
Rungsima Wanitphakdeedecha
Francesca Sy-Alvarado
Poramin Patthamalai
Thanya Techapichetvanich
Sasima Eimpunth
Woraphong Manuskiatti
Publikationsdatum
06.06.2020
Verlag
Springer London
Erschienen in
Lasers in Medical Science / Ausgabe 9/2020
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-020-03045-8